FDA MedWatch Reports for 9 Cases from Multiple Countries Including Mylan, Aurobindo, Takeda, Incyte, Astellas

FDA MedWatch Reports for 9 Cases from Multiple Countries Including Mylan, Aurobindo, Takeda, Incyte, Astellas

Regular price $69.00 USD
Regular price Sale price $69.00 USD
Sale Sold out
Original Request: MedWatch Reports for the following 9 cases: IT-MYLANLABS-2024M1091762 IT-AUROBINDO-AUR-APL-2024-049628 IT-TAKEDA-2024TUS100811 NVSC2024IT196107 GB-INCYTE CORPORATION-2024IN009439 US-INCYTE CORPORATION-2022IN006886 US-ASTELLAS-2017US016366 PL-INCYTE CORPORATION-2019IN002214 PHHY2017IT166445
Tags: Pharma, Adverse Event, 2024
  • Status: Pending Fast-Track Request
  • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. IMPORTANT: The FDA FOIA office operations are currently suspended. We are happy to make the request but do not know when we will receive a response. Learn more about Fast-Track Requests here.

View full details